Logo

AstraZeneca and Daiichi Report the US FDA's Acceptance of BLA for Trastuzumab deruxtecan (DS-8201) and Granted Priority Review

Share this

AstraZeneca and Daiichi Report the US FDA's Acceptance of BLA for Trastuzumab deruxtecan (DS-8201) and Granted Priority Review

Shots:

  • The BLA submission is based on P-I study and the pivotal P-II DESTINY-Breast01 study. The P-II DESTINY-Breast01 study assessing Trastuzumab deruxtecan in 253 patients with HER2+ unresectable/metastatic breast cancer prior treated with Trastuzumab Emtansine
  • The US FDA has granted Priority Review to Trastuzumab deruxtecan to treat patients with HER2+ mBC with its expected PDUFA date in Q2’20
  • Trastuzumab Deruxtecan is an ADC- delivers cytotoxic agents to the targeted cancer cell via linker attached to a mAb- currently evaluating in 5 trials for multiple cancer and has received FDA’s BT- FT & MHLW’s Sakigake designation for HER2+ LA/m-breast cancer & advanced HER2+ gastric cancer respectively

Click here to­ read full press release/ article 

Ref: AstraZeneca | Image: AstraZeneca


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions